T-cell agonists in cancer immunotherapy
Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...
Main Authors: | Cara L Haymaker, Yeonjoo Choi, Yaoyao Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000966.full |
Similar Items
-
Next-Generation Immunotherapies to Improve Anticancer Immunity
by: Yaoyao Shi, et al.
Published: (2021-01-01) -
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
by: Leila Motedayen Aval, et al.
Published: (2020-10-01) -
Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
by: Eun-Jin Go, et al.
Published: (2020-10-01) -
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
by: Melody Smith, et al.
Published: (2018-12-01) -
Development of a novel TLR8 agonist for cancer immunotherapy
by: Yuxun Wang, et al.
Published: (2020-09-01)